J&J wins snap approval of apalutamide, the first drug OK'd for nonmetastatic prostate cancer
The FDA has given J&J a big boost today, cutting its priority review for apalutamide down to a quick once over and a snap approval …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
